Curis, Inc.
NASDAQ:CRIS
3.46 (USD) • At close January 8, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | Curis, Inc. |
Symbool | CRIS |
Munteenheid | USD |
Prijs | 3.46 |
Beurswaarde | 29,295,682 |
Dividendpercentage | 0% |
52-weken bereik | 2.86 - 17.49 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. James E. Dentzer |
Website | https://www.curis.com |
An error occurred while fetching data.
Over Curis, Inc.
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)